Annual financial statements 2013: aap lays cornerstone to become the leading EU based trauma company

2013: Sales EUR 40 million (+10%); EBITDA EUR 7.0 million (+15%)

aap Implantate AG (XETRA: AAQ.DE), delivered on its financial and strategic goals, setting the stage for long term growth. We have made progress in 2013, especially in the growth of the Trauma business, further development of the technologies silver coating and magnesium alloys, the divestment of our non-core anti-adhesion product Adcon® and our orthopedic reconstructive implant business (hip, knee and shoulder products) as well as with the divestment of our contract manufacturing business (EMCM B.V.) early 2014.

Complete press release:
  • FINAL_ENG_PM_KJA2013_incl_Anlagen_20140331.pdf

This release contains forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap 's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments

For further information, please contact:

distributed by